The global Drug Discovery Informatics Market is projected to grow at a CAGR of 12.6% over the forecast period. Drug discovery is a multidisciplinary process used by researchers to encounter highly interconnected and complex meta data with the unprecedented availability of instrumentation and information technology. It is a capital-intensive, complicated, and a lengthy procedure, which demands expertise from pharmaceutical and multiple other scientific disciplines.
“The advanced information technology has redefined the traditional drug discovery process and the research productivity of computational chemistry application is providing substantial benefits to drug discovery informatics platform.”
Inexpensive computing is transforming the face of modern discovery informatics. The redefinition of drug discovery informatics is serving scientists with decision support tools and the rise in data culture is driving the growth of drug discovery informatics market.
Presently, the industry is facing major productivity challenges to efficiently generate pipelined products to replace the fading blockbusters of genomics. The rising research & development expenses and downward pricing pressures have emerged a potential threat to the industry growth. The swelling regulatory burden and lack of a worldwide governing harmony have added up to the challenges faced by the pharmaceutical vendors. The new entrants are increasingly organizing cross-functional working groups to evaluate the authenticity of these applications and methods to steer these methodologies for their unique discovery process. In an attempt to minimize cost restraints, the market players have found new technologies resulting in a shift from conventional methodologies towards modern-day technologies.
By process type, the drug discovery informatics market has found its segments across Sequencing & Target Data Analysis, Screening & ADMET characterization, Docking, Libraries & Database Preparation, and Molecular Modelling among others. Software and services have been identified as the key bifurcation of the solution segment of the market. Further breakdown of the end-user industry includes contract research organizations (CROs), pharmaceutical & biotechnology companies, and others (academic institutes and government organizations).
Furthermore, the industry players are increasing their investments to incorporate innovative service launches in order to enhance their prominence and survive the competitive edge. Drug development, marketing and its commercialization have been attributed has expensive and demands huge investments.
The increasing requirement of drugs to treat several diseases has propelled a number of merger and acquisition (M&A) activities aiming to meet complicated test targets. The drug discovery informatics have helped researches to make better decisions related to higher human anatomy. The big pharma companies are supplementing their overall drug discovery and delivery process by leveraging key competencies like partnerships and outsourcing their research activities to the organizations whose risk assessment are more compatible with financial structures. The industry participants are focusing on core competencies to foster efficient collaborations by outsourcing the areas that appear to be too risky and unclear.
The quest for enhanced efficiency of Drug Discovery, led to formation of ‘rational drug design’ in the 1980s. The development of operational informatics has propelled the concept of agile laboratory for chemical registration and IT systems that manages the flow of chemicals throughout the lab.
The competitive landscape showcases the profiles and business strategies of the major players, along with their recent developments. Some of the dominant players operating in this market include Thermo Fisher Scientific, Charles River Laboratories International, Inc., PerkinElmer Inc., Boehringer Ingelheim GmbH, Biogen Inc., Insilico Medicine, Inc., Schrödinger, International Business Machines Corporation, LLC, Certara, L.P, and Albany Molecular Research Inc. (AMRI) among others. In terms of sustainability and standardization, the drug discovery informatics market is opening new opportunities for savvy entrants to capitalize on the growing demand.
Drug Discovery Informatics Workflow Outlook (Revenue, USD Million, 2014 - 2025)
• Discovery Informatics
• Identification & Validation Informatics Assay Development Informatics
• Lead Generation Informatics
• Development Informatics
• Lead Optimization
• FHD Preparation
• Phase IA Informatics
• Phase IB/2 Informatics
Drug Discovery Informatics Mode Outlook (Revenue, USD Million, 2014 - 2025)
• In-house Informatics
• Outsourced Informatics
Drug Discovery Informatics Service Outlook (Revenue, USD Million, 2014 - 2025)
• Sequence Analysis Platforms
• Molecular Modeling
• Clinical Trial Data Management
Drug Discovery Informatics Regional Outlook (Revenue, USD Million, 2014 - 2025)
• North America
• Asia Pacific
• Latin America
• Middle East & Africa
• South Africa
Research Support Specialist, USA